Cargando…
Neurological adverse events associated with PD-1/PD-L1 immune checkpoint inhibitors
Immunotherapy is a promising method for cancer treatment. Among them, immune checkpoint inhibitors targeting PD-1/PD-L1 are increasingly used for certain cancers. However, with the widespread use of such drugs, reports of immune-related adverse events (irAEs) are also increasing. Neurological advers...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Frontiers Media S.A.
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10339650/ https://www.ncbi.nlm.nih.gov/pubmed/37456998 http://dx.doi.org/10.3389/fnins.2023.1227049 |